ArticleActa endocrinologica (Bucharest, Romania : 2005)
EFFECTS OF LIRAGLUTIDE ON BONE TURNOVER MARKERS AND BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS.
Article in Acta endocrinologica (Bucharest, Romania : 2005). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study examines the impact of liraglutide on bone turnover markers and bone mineral density (BMD) in individuals diagnosed with type 2 diabetes mellitus (T2DM). Patients and methods: A randomized controlled trial included 100 participants who were assigned to receive either liraglutide in combination with metformin (n=50) or metformin alone (n=50) for a duration of 48 weeks. Results: Analysis revealed statistically significant improvements in metabolic parameters, including glucose and lipid metabolism, in the liraglutide group compared to controls (P < 0.001). Notably, male participants exhibited enhanced bone turnover markers, evidenced by increases in N-terminal mid-region osteocalcin (N-MID) and total type I collagen amino-terminal propeptide (TPINP), alongside decreases in the C-terminal telopeptide of type I collagen (β-CTX). Conversely, female participants did not demonstrate significant changes in these markers. Additionally, liraglutide effectively mitigated BMD loss observed at the femoral neck and lumbar spine in the treatment group. These findings underscore liraglutide's potential benefits in metabolic regulation and its role in supporting bone health, particularly in male patients. Further research is essential to conclusively define these effects and elucidate the underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.